20.05.2021 • NewsArkemaBostikMergers & Acquisitions (M&A)

Arkema to Acquire Edge Adhesives Texas

French specialty chemicals producer Arkema said it plans to acquire Edge Adhesives Texas, as “a complementary asset” that will boost subsidiary Bostik’s offerings in high performance adhesives in the US. Financial terms were not disclosed.

Arkema said the deal, due to close in the current quarter, is in line with its growth strategy of bolt-on acquisitions to develop greater breadth in adhesives and deliver new products to meet expanding demand. It will expand Bostik’s profile and expand its presence in North America, the parent company added.

Edge Adhesives, which operates a plant in Fort Worth, Texas, is regarded as a leading developer and manufacturer of adhesive solutions used in residential buildings. With around 50 employees and annual sales of around $12 million, the company specializes in custom formulations in fast-growing easy-install window, door and roofing applications.

In addition to delivering strong technological, industrial and commercial synergies, Arkema said the acquisition will enable Bostik to offer its customers an extended range of value-added and sustainable solutions in hot-melt pressure sensitive adhesives. Based in Colombes, France, the company with annual sales of €2.1 billion develops, manufactures and distributes specialty adhesives and sealants for construction, industrial and consumer markets.

Author: Dede Williams, Freelance Journalist

Arkema plans to acquire Edge Adhesives Texas to boost subsidiary Bostik’s...
Arkema plans to acquire Edge Adhesives Texas to boost subsidiary Bostik’s offerings in high performance adhesives in the US. Financial terms of the deal, due to close during the current quarter, were not disclosed. The Texas firm has annual sales of $12 million and 50 employees. (c) Arkema

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read